BB Biotech AG (BION) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.033x

Based on the latest financial reports, BB Biotech AG (BION) has a cash flow conversion efficiency ratio of -0.033x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-59.96 Million ≈ $-75.81 Million USD) by net assets (CHF1.84 Billion ≈ $2.33 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

BB Biotech AG - Cash Flow Conversion Efficiency Trend (2003–2024)

This chart illustrates how BB Biotech AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does BB Biotech AG carry for a breakdown of total debt and financial obligations.

BB Biotech AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BB Biotech AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
RBL Bank Limited
NSE:RBLBANK
-0.317x
CREDITACCESS GRAMEEN LIMITED
NSE:CREDITACC
0.043x
5N Plus Inc.
TO:VNP
0.107x
Sarda Energy & Minerals Limited
NSE:SARDAEN
0.179x
ePlus inc
NASDAQ:PLUS
-0.082x
Wuhan PS Information Tech
SHE:300184
0.011x
BW LPG Limited
F:BW9
0.094x
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
0.000x

Annual Cash Flow Conversion Efficiency for BB Biotech AG (2003–2024)

The table below shows the annual cash flow conversion efficiency of BB Biotech AG from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see BB Biotech AG market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CHF2.29 Billion
≈ $2.89 Billion
CHF304.56 Million
≈ $385.05 Million
0.133x +41.78%
2023-12-31 CHF2.32 Billion
≈ $2.94 Billion
CHF218.28 Million
≈ $275.96 Million
0.094x +170.53%
2022-12-31 CHF2.69 Billion
≈ $3.40 Billion
CHF-357.81 Million
≈ $-452.37 Million
-0.133x -8.23%
2021-12-31 CHF3.29 Billion
≈ $4.16 Billion
CHF-404.81 Million
≈ $-511.79 Million
-0.123x -282.90%
2020-12-31 CHF3.90 Billion
≈ $4.93 Billion
CHF262.45 Million
≈ $331.81 Million
0.067x +6.19%
2019-12-31 CHF3.39 Billion
≈ $4.29 Billion
CHF215.02 Million
≈ $271.84 Million
0.063x +138.78%
2018-12-31 CHF2.88 Billion
≈ $3.65 Billion
CHF-471.34 Million
≈ $-595.90 Million
-0.163x -184.11%
2017-12-31 CHF3.54 Billion
≈ $4.47 Billion
CHF687.50 Million
≈ $869.19 Million
0.194x +172.74%
2016-12-31 CHF3.00 Billion
≈ $3.80 Billion
CHF-802.07 Million
≈ $-1.01 Billion
-0.267x -262.76%
2015-12-31 CHF3.98 Billion
≈ $5.03 Billion
CHF652.82 Million
≈ $825.34 Million
0.164x -61.02%
2014-12-31 CHF3.49 Billion
≈ $4.42 Billion
CHF1.47 Billion
≈ $1.86 Billion
0.421x -4.28%
2013-12-31 CHF2.12 Billion
≈ $2.68 Billion
CHF931.83 Million
≈ $1.18 Billion
0.440x +47.54%
2012-12-31 CHF1.23 Billion
≈ $1.56 Billion
CHF367.83 Million
≈ $465.04 Million
0.298x +76.14%
2011-12-31 CHF1.00 Billion
≈ $1.27 Billion
CHF169.52 Million
≈ $214.32 Million
0.169x +992.62%
2010-12-31 CHF1.23 Billion
≈ $1.56 Billion
CHF-23.41 Million
≈ $-29.60 Million
-0.019x -117.13%
2009-12-31 CHF1.52 Billion
≈ $1.92 Billion
CHF167.84 Million
≈ $212.19 Million
0.111x -67.30%
2008-12-31 CHF1.50 Billion
≈ $1.90 Billion
CHF509.39 Million
≈ $644.01 Million
0.339x +197.58%
2007-12-31 CHF1.77 Billion
≈ $2.23 Billion
CHF201.02 Million
≈ $254.14 Million
0.114x +1394.02%
2006-12-31 CHF2.25 Billion
≈ $2.85 Billion
CHF-19.80 Million
≈ $-25.04 Million
-0.009x -226.35%
2005-12-31 CHF2.28 Billion
≈ $2.88 Billion
CHF-6.14 Million
≈ $-7.76 Million
-0.003x -104.81%
2004-12-31 CHF1.91 Billion
≈ $2.42 Billion
CHF107.32 Million
≈ $135.68 Million
0.056x +163.12%
2003-12-31 CHF1.94 Billion
≈ $2.45 Billion
CHF-172.22 Million
≈ $-217.73 Million
-0.089x --

About BB Biotech AG

SW:BION Switzerland Biotechnology
Market Cap
$3.08 Billion
CHF2.43 Billion CHF
Market Cap Rank
#5844 Global
#82 in Switzerland
Share Price
CHF44.15
Change (1 day)
-0.79%
52-Week Range
CHF28.30 - CHF49.50
All Time High
CHF78.42
About

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more